Related Experiment Video

Updated: Jul 19, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Future trends in patient-reported outcomes assessment for patients with advanced-stage lung cancer receiving targeted

David T Eton1, Kathleen J Yost, David Cella

  • 1Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, IL 60201, USA. d-eton@northwestern.edu

Clinical Lung Cancer
|October 10, 2006
PubMed

Insights

Targeted therapies offer a tolerable alternative for advanced lung cancer patients. However, current quality of life assessments reveal gaps in measuring patient well-being with these novel treatments.

Area of Science:

  • Oncology
  • Pharmacology
  • Patient-Reported Outcomes

Background:

  • Targeted therapies represent a significant advancement in cancer treatment, offering a more tolerable alternative to traditional chemotherapy.
  • These novel agents target specific pathways crucial for cancer development and progression.
  • Clinical trials for advanced-stage lung cancer increasingly incorporate targeted therapies.

Purpose of the Study:

  • To review health-related quality of life (HRQoL) measures used in advanced-stage lung cancer clinical trials.
  • To identify measurement gaps in assessing patient well-being with emerging targeted therapies.
  • To suggest methods for addressing these identified gaps.

Main Methods:

  • Systematic review of commonly used HRQoL measures in advanced lung cancer trials.
  • Analysis of recently conducted clinical trials involving targeted lung cancer therapies.
  • Discussion of unique issues and methodological concerns for patients on targeted therapy.

Main Results:

  • Existing HRQoL measures adequately cover many patient-related outcomes.
  • The introduction of targeted therapies has exposed specific gaps in current measurement systems.
  • Key areas for improvement include assessing treatment efficacy perception, compliance, satisfaction, and convenience.

Conclusions:

  • While established HRQoL measures are valuable, they require refinement to fully capture the patient experience with targeted lung cancer therapies.
  • Addressing identified measurement gaps is crucial for a comprehensive understanding of targeted therapy's impact on patient well-being.
  • Further research should focus on developing and validating measures tailored to the unique aspects of targeted cancer treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...